company background image
AGN

Argenica TherapeuticsASX:AGN Stock Report

Market Cap

AU$27.8m

7D

-6.2%

1Y

n/a

Updated

20 Oct, 2021

Data

Company Financials
AGN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AGN Overview

Argenica Therapeutics Limited researches and develops a neuroprotective therapeutic drug in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Argenica Therapeutics
Historical stock prices
Current Share PriceAU$0.38
52 Week HighAU$0.18
52 Week LowAU$0.45
Beta0
1 Month Change-3.80%
3 Month Change85.37%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO46.15%

Recent News & Updates

Sep 16
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

AGNAU PharmaceuticalsAU Market
7D-6.2%1.8%1.7%
1Yn/a5.8%20.2%

Return vs Industry: Insufficient data to determine how AGN performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AGN performed against the Australian Market.

Price Volatility

Is AGN's price volatile compared to industry and market?
AGN volatility
AGN Beta0
Industry Beta1.3
Market Beta1

Stable Share Price: AGN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: Insufficient data to determine AGN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2019n/aLiz Dallimorehttps://argenica.com.au

Argenica Therapeutics Limited researches and develops a neuroprotective therapeutic drug in Australia. The company’s product is ARG-007, a neuroprotective peptide candidate for use in the protection of brain tissue against damage during a stroke and other acute central nervous system injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.

Argenica Therapeutics Fundamentals Summary

How do Argenica Therapeutics's earnings and revenue compare to its market cap?
AGN fundamental statistics
Market CapAU$27.81m
Earnings (TTM)-AU$1.03m
Revenue (TTM)AU$296.08k

94.1x

P/S Ratio

-27.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AGN income statement (TTM)
RevenueAU$296.08k
Cost of RevenueAU$0
Gross ProfitAU$296.08k
ExpensesAU$1.33m
Earnings-AU$1.03m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.014
Gross Margin100.00%
Net Profit Margin-347.72%
Debt/Equity Ratio0.0%

How did AGN perform over the long term?

See historical performance and comparison

Valuation

Is Argenica Therapeutics undervalued compared to its fair value and its price relative to the market?

4.06x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGN is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: AGN is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGN is overvalued based on its PB Ratio (4.1x) compared to the AU Pharmaceuticals industry average (3.5x).


Future Growth

How is Argenica Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

67.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Argenica Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Argenica Therapeutics performed over the past 5 years?

-56.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: AGN is currently unprofitable.

Growing Profit Margin: AGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if AGN's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare AGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: AGN has a negative Return on Equity (-15.04%), as it is currently unprofitable.


Financial Health

How is Argenica Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AGN's short term assets (A$7.3M) exceed its short term liabilities (A$425.7K).

Long Term Liabilities: AGN has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: AGN is debt free.

Reducing Debt: AGN has not had any debt for past 5 years.

Debt Coverage: AGN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AGN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Argenica Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

AU$145k

CEO Compensation


CEO

Liz Dallimore

no data

Tenure

AU$144,545

Compensation

Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD) is Chief Executive Officer of Argenica Therapeutics Limited. She is a research & development, innovation and commercialisation specialist with experience across...


CEO Compensation Analysis

Compensation vs Market: Liz's total compensation ($USD108.07K) is below average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Insufficient data to compare Liz's compensation with company performance.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: AGN only recently listed within the past 12 months.


Top Shareholders

Company Information

Argenica Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Argenica Therapeutics Limited
  • Ticker: AGN
  • Exchange: ASX
  • Founded: 2019
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$27.805m
  • Shares outstanding: 73.17m
  • Website: https://argenica.com.au

Location

  • Argenica Therapeutics Limited
  • 117 Broadway
  • Unit 4
  • Nedlands
  • Western Australia
  • 6009
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:36
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.